中药干预结合抗苗勒氏管激素预测对提高卵巢功能低下患者妊娠率的影响被引量：7

Effect of Chinese medicine intervention and anti-Mullerian hormone prediction on improving pregnancy rate in patients with hypofunction of ovary

下载PDF

导出

摘要卵巢储备功能(ovarian reserve)是指卵巢内存留卵泡的数量和质量,反映女性的生殖能力[1]。卵巢可募集的卵泡数过低,卵泡细胞质量下降,导致不能受孕,称为卵巢储备功能低下(decline in ovarian re-serve,DOR)[2]。DOR如不及时治疗,可导致卵巢早衰(premature ovarian failure,POF)发生[3]。

作者邵梅章勤

机构地区杭州市中医院妇二科

出处《浙江中西医结合杂志》 2019年第1期42-45,共4页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

基金杭州市科技发展计划项目(No.20150733Q54) 浙江省中医药科技计划基金项目(No.2016ZA147)

关键词卵巢储备功能低下抗苗勒氏管激素再生育人群

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献14

1王清秀.卵巢早衰与储备功能下降的相关因素探讨[J].当代医学,2012,18(11):94-95. 被引量：13
2程萍,张丽萍,刘永珍.抗苗勒激素对体外受精-胚胎移植结局的预测作用[J].湖北医药学院学报,2012,31(1):7-10. 被引量：3
3贺晶,罗洁.再生育的临床问题[J].中华妇幼临床医学杂志（电子版）,2014,10(2):1-5. 被引量：33
4聂超凤,卢芳梅,黄秋云.血清抗苗勒管激素及性激素检测对卵巢早衰诊断预测的临床价值[J].深圳中西医结合杂志,2016,26(4):87-88. 被引量：18
5赖爱鸾,孙艳格,张李松,金巧凤,王丽芳,朱海燕.性激素、年龄、月经模式变化对卵巢储备功能的预测价值[J].中国实用妇科与产科杂志,2010,26(9):717-719. 被引量：38
6胡琳莉,孙莹璞.美国妇产科医师学会及美国生殖医学会“与年龄相关的女性生育力减退共识”解读[J].中国实用妇科与产科杂志,2015,31(8):696-698. 被引量：16
7胡琳莉,朱桂金.抗苗勒激素(AMH)在卵巢中的作用[J].中国优生与遗传杂志,2006,14(3):7-8. 被引量：8
8胡蓉,张晓梅,吴昕,包俊华.抗苗勒氏管激素(AMH)预测卵巢储备功能及反应性的研究[J].生殖与避孕,2009,29(8):515-519. 被引量：37
9陈晓,季银芬,徐键.抗苗勒氏管激素(AMH)与多囊卵巢综合征(PCOS)卵泡发育异常的关系[J].生殖与避孕,2014,34(5):383-387. 被引量：46
10苏先芝,史云.卵巢储备功能评估的研究进展[J].国际生殖健康／计划生育杂志,2017,36(3):260-264. 被引量：22

二级参考文献161

1赵晓明,毛宇红,刘芳荪,孙赟,洪燕,林其德.卵巢储备功能测定在体外受精(IVF)技术中的临床价值探讨[J].生殖与避孕,2005,25(8):465-468. 被引量：13
2叶云,吴日然,廖月婵,杜彦,张旭宾,程敬松.血清抑制素B检测值预测卵巢储备功能的临床研究[J].中国优生与遗传杂志,2006,14(3):107-108. 被引量：12
3Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-miillerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab, 2000, 85(2):540-4.
4Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum miillerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002, 77(3): 468-71.
5Kansal Kalra S, Ratcliffe S, Gracia CR, et al. Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reprod Biomed Online, 2008, 17 (6):745-50.
6Golan A, Ron-EI R, Herman A, et al. OHSS: an update review. Obstet Gynecol Surv,1989, 44(6):430-40.
7Deffieux X, Antoine JM. Inhibins, activins and anti Mullerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine. Gynecol Obstet Fertil, 2003, 31(11):900-11.
8Rajpert-DeMeyts E, Jorgensen N, Graem N, et al. Expression of anti-Mtillerian hormone during normal and pathological gonadal development association with differentiation of Sertoli and granulose cells. J Clin Endocrinol Metah, 1999, 84 (10):3836-44.
9Baarends WM, Uilenbroek JT, Kramer P. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development,the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology, 1995, 136(10):4951-62.
10Hazout A, Bouchard P, Seifer DB, et al. Serum antimullerian inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril, 2004, 82(5): 1323-9.